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AbSTrACT
background Performing mechanical thrombectomy 
(MT) in patients with basilar artery occlusion (BaO) is 
currently not evidence-based.
Objective To compare patients’ outcome, relative 
merits of achieving recanalization, and predictors of futile 
recanalization (Fr) between BaO and anterior circulation 
large vessel occlusion (aclVO) MT.
Methods in the multicenter BeYOnD-sWiFT registry 
(ncT03496064), univariate and multivariate (displayed 
as adjusted Odds ratios, aOr and 95% confidence 
intervals, 95%-ci) outcome comparisons between BaO 
(n=165) and aclVO (n=1574) were performed. The 
primary outcome was favorable outcome at 90 days 
(modified rankin scale, mrs 0-2). secondary outcome 
included mortality, symptomatic intracranial hemorrhage 
(sich) and Fr. The relative merits of achieving successful 
recanalization between aclVO and BaO were evaluated 
with interaction terms.
results MT in BaO was more often technically effective 
and equally safe in regards to mortality and sich when 
compared to aclVO. When adjusting for baseline 
differences, there was no significant difference between 
BaO vs aclVO regarding rates of favorable outcome 
(aOr 0.986, 95%-ci 0.553 – 1.758). however, BaO 
were associated with increased rates of Fr (aOr 2.146, 
95%-ci 1.267 – 3.633). Predictors for Fr were age, 
stroke severity, maneuver count and intracranial stenting. 
no significant heterogeneity on the relative merits of 
achieving successful recanalization on several outcome 
parameters were observed when comparing BaO and 
aclVO.
Conclusions in selected patients, similar outcomes can 
be achieved in BaO and aclVO patients treated with MT. 
randomized controlled trials comparing patient selection 
and interventional strategies seem warranted to avoid 
Fr.
Trial registration number ncT03496064
InTrOduCTIOn
About 1% of patients with acute ischemic stroke have 
a basilar artery occlusion (BAO) that is amendable 
to endovascular treatment.1 2 Such patients present 
with particularly severe symptoms and have a poor 
prognosis compared with those with anterior circu-
lation large vessel occlusion (ACLVO).3 4 
In patients with BAO and other large vessel 
occlusions (LVOs) of the posterior circulation (PC), 
indications for mechanical thrombectomy (MT) 
lack evidence derived from large pivotal throm-
bectomy trials.5 6 Intravenous thrombolysis (IVT) 
is therefore the standard of care in those patients.7 
Yet, IVT yields insufficient acute reperfusion rates 
in patients with BAO.8–13 Therefore, many patients 
subsequently deteriorate clinically and tend to have 
poor outcomes if reperfusion is not achieved.8 14
Recanalization rates of MT were reported to 
be lower than with AC occlusions and procedure 
time longer.15 Furthermore in BAO, poor outcome 
despite successful recanalization by MT was 
reported to occur more frequently—a phenomenon 
termed futile recanalization (FR) (modified Rankin 
Scale (mRS) score 4–6 despite complete recanali-
zation).15–18 In this setting, ethics and patient pref-
erences are taken into account when considering 
the risk of subjecting patients to a treatment that 
may avoid death but instead creates long-term 
dependence.19 20 Efforts have been made to identify 
predictors of FR in BAO—namely, stroke severity 
on admission, amount of radiological lesion on 
baseline MRI or CT, respiratory instability, and 
collateral quality.16–18 21 22 Despite those efforts, the 
rates of long-term dependence were reported to be 
around 30%23 after MT in BAO.
Although several studies have reported predic-
tors of outcome after endovascular therapy in 
patients with BAO, few studies have focused solely 
on MT. Furthermore, reports were limited by small 
numbers of patients, non-transparent patient selec-
tion, heterogeneous endovascular treatments, and 
inclusion of patients with more distal occlusions.
The aims of this study were hence to compare 
patients’ outcome, the relative merits of achieving 
recanalization, predictors of FR, and procedural 
safety between BAO and ACLVO MT, and predic-
tors of FR in BAO.
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MeThOdS
Details of the BEYOND-SWIFT Registry are in the public 
domain (NCT03496064) and have been published previously.24 
Briefly, the registry is a retrospective, multicenter, non-random-
ized observational study designed to investigate the safety and 
efficacy of a Medtronic market-released neurothrombectomy 
device (applied as the initial device used for interventions) in 
patients with acute ischemic stroke who do not fulfill treatment 
eligibility requirements according to the current guidelines. An 
overview of the patients included in the registry, the follow-up 
data for each center, and ethical approval procedures can be 
found in online supplementary table I. Ethical approval was 
obtained in Bern for pooling and analyses of the registry data 
(KEK Bern, Bern, Switzerland ID 2018–00766).
Most patients included in the registry (n=2046) were treated 
for large-vessel anterior circulation strokes (n=1832). Of the 
patients treated for BAO (n=165), 152 (92.1%) had docu-
mented 90-day follow-up. Selection criteria for performing MT 
in BAO were center-specific and are presented in online supple-
mentary table 5.
Variables and image analysis
Local investigators categorized the site of LVO into vertebral 
artery, basilar artery, or first/second segment of the posterior 
cerebral artery (P1/P2) occlusions. For the main analysis we 
compared patients with BAO with those with iICA/carotid-T/
M1-occlusions. Either the operator at each center or an inde-
pendent research fellow rated the postprocedural modified 
Thrombolysis in Cerebral Infarction (mTICI) score (see online 
supplementary table I). mTICI 2b was rated as reperfusion of 
at least 50% of the initially occluded target vessel territory, 
according to modifications of the TICI scale.25 For clinical 
outcome evaluation, we assessed 3-month functional outcomes 
using the mRS score in routinely scheduled clinical visits or stan-
dardized telephone interviews organized at each center. FR was 
defined as successful recanalization in patients with mRS score 
4–6 at 90 days.20 Worsening in the National Institutes of Health 
Stroke Scale (NIHSS) score of ≥4 points between the admission 
NIHSS score and the score 24 hours later, and not attributable 
to an intracerebral hemorrhagic event was defined as non-hem-
orrhagic worsening.26
Statistical analysis
Univariate comparisons between patients with BAO or ACLVO, 
between patients with favorable outcome (mRS score 0–2) and 
patients with unfavorable outcome (mRS score 3–6), as well as 
between patients with futile and non-futile recanalization were 
made using standard statistical measures (Fisher’s exact test for 
categorical variables, Mann–Whitney U test for non-normally 
continuous or ordinally scaled variables, and Welsch’s t-test for 
independent normally distributed data).
The primary endpoint of this analysis was favorable outcome 
at 90 days (mRS score 0–2) in BAO versus ACLVO according 
to multivariate analysis. Secondary outcomes consisted of rate 
of successful recanalization, FR, all-cause mortality at day 90, 
overall complication rate, and symptomatic intracerebral hemor-
rhage (sICH), which was assessed at each center by applying the 
ECASS II criteria, although they were originally established 
for AC strokes. The association between BAO versus ACLVO 
with all of the previously listed outcome parameters was hence 
assessed using multivariable logistic regression with adjustments 
for the following confounders: age (continuous), prestroke inde-
pendence (categorical), NIHSS score on admission (ordinal, 
adjusted odds ratio (aOR) per point increase), systolic blood 
pressure (metric, aOR per mm Hg increase), known onset 
(categorical), risk factor hypertension (categorical), risk factor 
smoking (categorical), risk factor previous stroke (categorical), 
risk factor diabetes (categorical), type of admission imaging (CT 
vs MRI, categorical), IVT (categorical), and time from symptom 
onset to admission (metric, aOR per minute increase). The 
adjustments were made according to significant baseline differ-
ences in univariate analysis, except for admission glucose levels 
and history of coronary heart disease since too many data items 
were missing.
A potential difference in the relative merits of achieving 
successful recanalization between BAO and ACLVO was evalu-
ated with interaction terms. For this comparison, we assessed the 
relative effect of successful recanalization on various dichotomi-
zations of functional outcome and safety parameters using multi-
variable logistic regression with adjustments for the following 
prespecified confounders: age (continuous), sex (categorical), 
NIHSS score on admission (ordinal, aOR per point increase) and 
IVT (categorical). The adjustments for this analysis were made 
according to a clinical assumption of the main confounders as 
the restricted number of patients without successful recanaliza-
tion limited the number of variables that could be included.
reSulTS
baseline
For baseline differences, the 165 patients with BAO were 
younger, more often male, more often transferred from other 
hospitals, had more severe symptoms on admission, higher 
glucose on admission, less often anticoagulation pretreatment, 
less often hypertension, less often dyslipidemia, other TOAST 
etiology, and MRI was less often performed as the initial imaging 
modality (table 1) as compared with ACLVO. Furthermore, time 
from symptom onset to groin puncture was longer in BAO than 
in ACLVO (median 300 min vs 225 min, p<0.001).
Technical efficacy
Comparison of MT in patients with BAO and patients with 
ACLVO showed that the procedure was more often effective in 
BAO, with achievement of a mTICI 3 recanalization in 61.8% 
and a mTICI 2b/3 in 90.3% of patients requiring fewer maneu-
vers (p=0.002). Groin puncture to recanalization intervals in 
patients with BAO were similar to those in ACLVO (median 
45 min vs 47 min, p=0.824). However, more intracranial stents 
were used in patients with BAO (17.0% vs 2.3%, p<0.001) and 
longer times from symptom onset to groin-puncture (300 min vs 
225 min, p<0.001) were noted, probably because interventions 
usually required general anesthesia (88.2% vs 54.9%, p<0.001) 
(table 2). Also on multivariate analysis with adjustments for 
baseline differences, MT in BAO was associated with higher 
odds of achieving TICI 3 (aOR=2.004, 95% CI 1.227 to 3.274, 
p=0.005) and successful recanalization ≥TICI 2b (aOR=2.740, 
CI 1.145 to 6.554).
Safety
Safety endpoints, including sICH, systemic bleeding, craniec-
tomy, and complication rates, were less frequent in patients 
with BAO than in patients with ACLVO (table 2), but the differ-
ence did not reach statistical significance. Also on multivariate 
analysis, MT in BAO as compared with ACLVO was not asso-
ciated with either sICH (aOR=0.773, 95% CI 0.228 to 2.618) 
or mortality (aOR=1.612, 95% CI 0.891 to 2.918). However, 
patients with MT in BAO more often had postinterventional 
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non-hemorrhagic worsening (aOR=2.797, CI 1.366 to 5.726) 
than in ACLVO.
Outcome
Patients with BAO had worse outcomes than patients with 
ACLVO, as shown by a lower rate of moderate outcome (mRS 
score 0–3, 46.1% vs 56.7%, p=0.013) and a higher mortality 
rate (36.2% vs 24.4%, p=0.002), although rates of excellent 
functional outcome (mRS score 0–1, 25.0% vs 27.3%, p=0.631) 
and favorable outcome (mRS score 0–2, 36.2% vs 42.9%, 
p=0.120) were comparable in an unadjusted analysis (online 
supplementary table 2).
Baseline differences of patients with favorable outcome (mRS 
score 0–2) and unfavorable outcome (mRS score 3–6) can be 
found in online supplement table 3 and favoured neither BAO 
nor ACLVO. After adjusting for baseline differences, there was 
Table 1 Baseline characteristics comparing patients with basilar artery occlusion and patients with large vessel occlusion in the anterior circulation
Characteristics bAO (n=165)
AClVO (intracranial carotid artery, 
carotid-T, M1) (n=1574) P value
Clinical items
  Age (years) 70 (59–80), N=165 73 (61–82), N=1574 0.019
  Transfer from another hospital 80/165 (48.5%) 561/1572 (35.7%) 0.002
  Sex (female) 69/165 (41.8%) 810/1574 (51.5%) 0.022
  NIHSS on admission 18 (8–30), N=155 17 (12–20), N=1558 0.046
  Prestroke independence 149/164 (90.9%) 1446/1556 (92.9%) 0.341
  Blood pressure systolic (mm Hg) 148 (SD 31), N=86 150 (SD 28), N=1141 0.413
  Blood pressure diastolic (mm Hg) 78 (SD 16), N=86 82 (SD 20), N=1139 0.097
  Admission glucose (mmol/L) 7.5 (6.4–9.7), N=93 6.6 (5.8–8.1), N=1181 <0.001
  Wake-up stroke 13/161 (8.1%) 123/1451 (8.5%) 1.000
  TOAST etiology 0.008
   Large artery 37/163 (22.7%) 205/1546 (13.3%) 
   Cardioembolic 64/163 (39.3%) 733/1546 (47.4%) 
   Other specific etiology 12/163 (7.4%) 101/1546 (6.5%) 
   Unknown etiology 50/163 (30.7%) 507/1546 (32.8%)
Medication 0.058
  Antiplatelet 
   Monotherapy 36/154 (23.4%) 430/1463 (29.4%) 
   Dual therapy 0 (0%) 26/1463 (1.8%)
  Statin 32/142 (22.5%) 395/1300 (30.4%) 0.053
  Anticoagulation 0.014
 VKA 10/154 (6.5%) 180/1464 (12.3%)
   NOAC 2/154 (1.3%) 64/1464 (4.4%) 
Risk factors
  Diabetes 23/163 (14.1%) 271/1555 (17.4%) 0.326
  Arterial hypertension 87/163 (53.4%) 1046/1553 (67.4%) <0.001
  Dyslipidemia 60/161 (37.3%) 788/1547 (50.9%) 0.001
  Smoking 47/153 (30.7%) 428/1499 (28.6%) 0.574
  Previous stroke 17/159 (10.7%) 209/1565 (13.4%) 0.389
  Coronary artery disease 17/83 (20.5%) 235/1131 (20.8%) 1.000
Type of imaging 0.010
   MRI 42/165 (25.5%) 994/1544 (64.4%)
   CT 123/165 (74.5%) 550/1544 (35.6%)
Treatment
  IVT use 71/165 (43.0%) 779/1574 (49.5%) 0.120
  Time from onset of symptoms to IVT needle (min) 165 (113–210), N=39/71 120 (83–165), N=437/779 0.003
  Time from onset of symptoms to admission in stroke 
center (min)
228 (IQR 121–369), N=132 143 (71–245), N=1380 <0.001
  Time from onset of symptoms to groin puncture (min) 300 (IQR 211–480), N=133 225 (165–315), N=1346 <0.001
ACLVO, anterior circulation large-vessel occlusion; BAO, basilar artery occlusion; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-
vitamin K antagonist oral anticoagulants;TOAST, Trial of ORG 10172 in Acute Stroke Treatment; VKA, vitamin K antagonist.Difference in numbers of observations and total 
numbers of patients in each group due to missing data items.
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no significant difference in excellent (aOR=0.893, 95% CI 0.478 
to 1.669), favorable (primary outcome, aOR=0.986, 95% CI 
0.553 to 1.758, figure 1) and moderate functional outcome at 
90 days (aOR=0.692, 95% CI 0.396 to 1.121).
In conclusion, patients with BAO had worse outcomes on 
univariate analysis, but after adjustment for baseline differences, 
we could observe no significant differences of outcome of MT in 
BAO vs ACLVO, except an increased occurrence of FR.
FR was found more often in BAO than in ACLVO 
(aOR=2.146, CI 1.267 to 3.633). Factors associated with FR in 
univariate analysis were older age, higher stroke severity, coro-
nary artery disease, higher maneuver count, and intracranial 
stenting (table 3). Prestroke dependence, lower posterior circu-
lation Alberta Stroke Program Early CT Score (pcASPECTS), 
longer time from groin puncture to recanalization and adminis-
tration of additional intra-arterial thrombolytic agents showed a 
trend towards association with FR.
On unadjusted analysis, better outcomes were observed in 
patients with successful recanalization of BAO (online supple-
ment table 4) as compared with patients without successful 
recanalization. The relative benefit of achieving successful 
recanalization for various dichotomizations of the mRS 
scale, mortality, and sICH were comparable between patients 
presenting with recanalization of BAO and ACLVO according 
to multivariable binary logistic regression analysis, adjusting 
for prespecified confounders outlined in the methods section 
(figure 2). However, significantly higher rates of independence 
at 3 months were found only in the cohort of patients presenting 
with ACLVO.
In successfully recanalized BAO patients (TICI ≥2b, n=149), 
excellent recanalization (TICI 3, n=102) approached signifi-
cance to increase the odds of a favorable outcome (mRS 0–2) 
at day 90 (aOR=2.177, 95% CI 0.923 to 5.135) and decreased 
the odds of all-cause mortality at day 90 (aOR=0.408, 95% CI 
0.177 to 0.937).
dISCuSSIOn
This registry-based retrospective analysis of patients with BAO 
treated with stent-retriever MT has the following main findings: 
Table 2 Safety and efficacy data comparing patients with basilar artery occlusion and patients with large vessel occlusion in the anterior 
circulation
MT of bAO (n=165) MT of AClVO (n=1574) P value
Efficacy
  mTICI 3 102/165 (61.8%) 706/1571 (44.9%) <0.001
  mTICI ≥2b 149/165 (90.3%) 1299/1571 (82.7%) 0.011
  Time from groin puncture to recanalization (min) 45 (30–81), N=153 47 (30–75), N=1471 0.824
  General anesthesia 142/161 (88.2%) 792/1442 (54.9%) <0.001
  Additional intra-arterial thrombolytic agents 18/160 (11.3%) 112/1443 (7.8%) 0.127
  Maneuver count 1 (IQR 1–2), N=101 2 (1–3), N=1106 0.002
  Intracranial stenting 28/165 (17.0%) 36/1572 (2.3%) <0.001
  Extracranial stenting 13/165 (7.9%) 182/1572 (11.6%) 0.194
Safety
  sICH ECASS II definition 8/165 (4.8%) 98/1562 (6.3%) 0.608
  Systemic bleeding 1/39 (2.6%) 21/637 (3.3%) 1.000
  Craniectomy 4/161 (2.5%) 51/1448 (3.5%) 0.649
  Any interventional complication 18/165 (10.9%) 198/1572 (12.6%) 0.620
  Complications  ► Two vasospasms
 ► Five dissections
 ► Three perforations
 ► Two emboli to new territory
 ► Six other
 ► 51 vasospasms
 ► 37 dissections
 ► 21 perforations
 ► 59 emboli to new territory
 ► 32 other
ACLVO, anterior circulation large vessel occlusion; BAO, basilar artery occlusion; MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarction; sICH, 
symptomatic intracranial hemorrhage according to the European Cooperative Acute Stroke Study II definition.Difference in numbers of observations and total numbers of 
patients in each group due to missing data items. 
Figure 1 Comparison of outcomes of mechanical thrombectomy (MT) 
in posterior versus anterior circulation. Adjusted OR of MT in basilar 
artery occlusion versus anterior circulation large vessel occlusion for 
outcome parameters in the binary multivariable logistic regression 
analysis, adjusting for age, National Institutes of Health Stroke Scale 
score on admission, systolic blood pressure, prestroke independence, 
known onset, diabetes, arterial hypertension, smoking, previous 
stroke, imaging type, intravenous thrombolysis, and time from onset to 
admission. mRS, modified Rankin scale; sICH, symptomatic intracranial 
hemorrhage; TICI, Thrombolysis in Cerebral Infarction.
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Table 3 Baseline and interventional differences of patients with futile and non-futile reperfusion
Futile recanalization (n=70) non-futile recanalization (n=79) P value
Clinical items
  Age (years) 74 (63–81), N=70 67 (57–79), N=79 0.025
  Transfer from another hospital 34/70 (48.6%) 37/79 (46.8%) 0.870
  Sex (female) 34/70 (48.6%) 30/79 (38.0%) 0.246
  NIHSS score on admission 21 (12–36), N=65 12 (6–23), N=75 0.002
  Prestroke independence 60/70 (85.7%) 75/79 (94.9%) 0.089
  Blood pressure systolic (mm Hg) 154 (SD 32), N=41 144 (SD 28), N=39 0.170
  Blood pressure diastolic (mm Hg) 78 (SD 17), N=41 78 (SD 15), N=39 0.840
  Admission glucose (mmol/L) 7.6 (6.3–9.3), N=45 7.4 (6.4–9.8), N=41 0.959
  Noticed symptom onset 50/70 (71.4%) 62/79 (78.5%) 0.347
  Wake up 7/70 (10.0%) 5/77 (6.5%) 0.551
  In-hospital stroke 2/70 (2.9%) 0/79 0.219
Medication 0.417
  Antiplatelet 
   Monotherapy 17/67 (25.4%) 14/75 (18.7%) 
   Dual therapy 0/67 0/75
  Statin 15/63 (23.8%) 12/69 (17.4%) 0.394
  Anticoagulation 0.401
   None 63/67 (94.0%) 69/75 (92.0%) 
   VKA 4/67 (6.0%) 4/75 (5.3%) 
   NOAC 0/67 2/75 (2.7%)
Risk factors
  Diabetes 10/69 (14.5%) 9/79 (11.4%) 0.628
  Arterial hypertension 36/69 (52.2%) 40/79 (50.6%) 0.870
  Dyslipidemia 26/67 (38.8%) 26/79 (32.9%) 0.491
  Smoking 16/65 (24.6%) 25/74 (33.8%) 0.267
  Previous stroke 8/67 (11.9%) 8/79 (10.1%) 0.794
  Coronary artery disease 11/35 (31.4%) 4/40 (10.0%) 0.040
  TOAST etiology 
  
0.286
   Large artery 13/69 (18.8%) 21/79 (26.6%) 
   Cardioembolic 27/69 (39.1%) 33/79 (41.8%) 
   Other specific etiology 4/69 (5.8%) 7/79 (8.9%)
   Unknown etiology 25/69 (36.2%) 18/79 (22.8%)
Type of imaging 1.000
  MRI 16/70 (22.9%) 19/79 (24.1%) 
  CT 54/70 (77.1%) 60/79 (75.9%)
  pcASPECTS 7 (5–9), N=25 8 (7–9), N=24 0.076
Treatment
  IVT use 29/70 (41.4%) 33/79 (41.8%) 1.000
  Time from onset of symptoms to IVT needle (min) 165 (117–225), N=21/29 178 (109–228), N=16/33 0.914
  Time from onset of symptoms to admission (min) 240 (122–446), N=55 222 (112–335), N=67 0.231
  Time from onset of symptoms to groin puncture (min) 305 (211–539), N=55 300 (200–450), N=67 0.365
  Time groin to recanalization (min) 47 (34–86), N=67 41 (28–68), N=76 0.096
  General anesthesia 61/70 (87.1%) 68/77 (88.3%) 1.000
  Additional intra-arterial thrombolytic agents 11/70 (15.7%) 4/76 (5.3%) 0.055
  Balloon-guiding catheter 2/70 (2.9%) 7/76 (9.2%) 0.169
  Intracranial stent 17/70 (24.3%) 7/79 (8.9%) 0.014
  Extracranial stent 3/70 (4.3%) 8/79 (10.1%) 0.219
Continued
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(1) In comparison with patients presenting with ACLVO, inter-
ventional procedures in patients with BAO were more often 
technically effective and equally safe as regards mortality and 
sICH. (2) FR occurred more frequently in BAO, and predictors 
of FR included age, stroke severity, maneuver count, and intra-
cranial stenting. (3) Patients with MT in BAO had worse func-
tional outcome than in ACLVO on univariate analysis, but after 
multivariable adjustment, this difference was non-significant. 
(4) Successful recanalization in patients with BAO had similar 
associations with lower mortality, lower rates of sICH, and func-
tional outcome as seen in ACLVO.
The recanalization rate of 90.3% in BAO from our study is in 
line with recent MT observational studies,27 although it is slightly 
higher than in other systematic reviews, which included earlier 
studies10 17 and recent registries.15 28 Advances in MT technique, 
operator adjudication,29 use of TICI score in PCLVO30 in our 
registry, and different patient selection probably best explain the 
differences observed.
The rate of complications in patients with BAO was 10.9%, 
which was similar to rates previously reported31 32 and matched 
the frequency of complications seen in patients presenting with 
ACLVO.31 Serious complications observed were three artery 
perforations with one associated death. Patients with unsuc-
cessful recanalization had a higher complication rate (31.3% vs 
8.7%, p=0.018).
Irrespective of treatment modalities, patients with BAO 
more often have a deleterious course than their counterparts 
presenting with ACLVO.2 33 The mortality rate of 36.2% is in 
line with the published data.17 In accordance with previous data, 
we found a higher chance for FR in BAO than in ACLVO (47% 
vs 34%, p=0.002).15–18 Regarding factors associated with FR, 
our data confirm previously reported preinterventional factors, 
including age, baseline NIHSS score and lower pcASPECTS. 
Contrary to the literature, cardioembolic stroke subtype was 
no predictor of FR in our study. Importantly, we could identify 
interventional predictors of FR, mainly higher maneuver count 
and intracranial stenting. After adjusting for confounders, only 
age, baseline NIHSS score, and intracranial stenting remained 
significant prognostic factors for FR in our dataset. Together 
with a lower mortality rate in successfully recanalized patients, 
the observation of increased FR suggests that by MT, death 
was avoided but long-term dependence created. Those finding 
should be included in the discussion to treat or withhold treat-
ment according to patient preferences.
Corroborating our observations about the beneficial effect 
of successful recanalization, the meta-analyses by Kumar et al 
also reported that mortality was bisected in patients in whom 
successful recanalization (mTICI 2b or mTICI 3) was achieved.10 
Although partially present on unadjusted analysis, the higher 
rates of moderate, favorable, and excellent functional outcome 
were not statistically significant after adjustment for confounders 
when recanalization was achieved in BAO, although this could 
be shown by others.14 28 34 The small number of patients in 
whom recanalization could not be achieved was associated with 
broad confidence intervals, which probably explains the lack of 
statistical significance. More importantly, the effect of achieving 
successful recanalization with respect to mortality rates and 
sICH was independent of IVT administration. Sensitivity anal-
ysis disclosed no interaction between IVT and recanalization 
success.
It is noteworthy that excellent recanalization (TICI 3) was 
more beneficial for all-cause mortality at day 90 compared with 
successful recanalization (TICI ≥2b), which could be also shown 
in ACLVO.35–37 Therefore, also in BAO, efforts should be made 
to improve the quality of recanalization by preventing or treating 
distal emboli.38
Kumar et al concluded that the significant treatment effect of 
recanalization, confirmed by observational data and meta-anal-
yses in this severe disease, would make a randomized controlled 
trial (RCT) to compare MT and the best medication-based treat-
ment unethical.10 However, at least two such RCTs are currently 
being conducted.39 40 In our opinion, the most relevant question 
is not whether or not to treat patients with BAO with MT, but 
rather in which patients recanalization would be futile or cause 
long-term dependence. Therefore, RCTs comparing patient 
selection strategies with advanced imaging techniques and 
concomitant medical therapy are urgently warranted. Possible 
Futile recanalization (n=70) non-futile recanalization (n=79) P value
  Any interventional complication 7/70 (10.0%) 6/79 (7.6%) 0.773
  Maneuver 1 (1–2), N=45 1 (1–2), N=50 0.016*
  sICH ECASS II 2/70 (2.9%) 2/79 (2.5%) 1.000
*Maneuver count higher in futile recanalization.
IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants; pcASPECTS, posterior circulation Alberta 
Stroke Program Early CT Score; sICH, symptomatic intracranial hemorrhage according to the European Cooperative Acute Stroke Study II definition; TOAST, Trial of ORG 10172 in 
Acute Stroke Treatment; VKA, vitamin K antagonist.Difference in numbers of observations and total numbers of patients in each group due to missing data items. 
Table 3 Continued 
Figure 2 Effect of successful reperfusion on outcomes stratified for 
posterior versus anterior circulation. Adjusted OR of achieving successful 
recanalization (modified Thrombolysis in Cerebral Infarction ≥2b/3) for 
outcome parameters stratified for patients with basilar artery occlusion 
versus anterior circulation. Notice the broad CIs in the posterior 
circulation due to the small number of patients in whom recanalization 
could not be achieved. Numbers indicate the p value for interaction of 
IV thrombolysis and successful recanalization in the binary multivariable 
logistic regression analysis, including age, sex, National Institutes of 
Health Stroke Scale score on admission, and IV thrombolysis. BAO, 
basilar artery occlusion; mRS, modified Rankin scale; sICH, symptomatic 
intracranial hemorrhage.
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predictors for good outcome including stroke risk factors, stroke 
severity (NIHSS score), age, respiratory stability, thrombus 
length, atherosclerotic stenosis versus embolic occlusion, and 
collateral status have been published.14 41–52 They should be 
combined in a study protocol of patient selection in BAO to 
minimize the incidence of futile recanalization.
limitations
This is a single-arm multicenter retrospective registry, which 
has associated limitations. No comparison with patients treated 
with medical management only was performed, and patient 
selection for MT was center-specific. Several factors, including 
final mTICI score and initial pcASPECTS, were not adjudicated 
by a core laboratory and the exact location of BAO (proximal, 
middle, distal portion) was unknown. Data quality was incom-
plete for important predictors of outcome, such as collateral 
quality and pcASPECTS. Subgroup analyses were generally 
confined to small cohorts, which introduces a large uncertainty 
of the presented effects, as indicated by relatively wide confi-
dence intervals.
COnCluSIOn
In selected patients treated with MT, similar outcomes can be 
achieved in BAO and ACLVO. Patients with BAO in whom 
recanalization could be achieved, had lower mortality and rate 
of sICH than those with unsuccessful recanalization, without 
effect heterogeneity in comparison with ACLVO. The aim of 
MT should be complete recanalization. RCTs comparing patient 
selection and interventional strategies to avoid futile interven-
tions seem warranted.
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